Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas

Neuro-Oncology

Volumn 16, Issue 1, 2014, Pages 123-130

  Lin, Andrew L ^a   Liu, Jingxia ^a   Evans, John ^a   Leuthardt, Eric C ^a   Rich, Keith M ^a   Dacey, Ralph G ^a   Dowling, Joshua L ^a   Kim, Albert H ^a   Zipfel, Gregory J ^a   Grubb, Robert L ^a   Huang, Jiayi ^a   Robinson, Clifford G ^a   Simpson, Joseph R ^a   Linette, Gerald P ^a   Chicoine, Michael R ^a   Tran, David D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1p 19q codeletions; oligoastrocytoma; oligodendroglioma; p53.; pseudoprogression

Indexed keywords

ADULT; ARTICLE; ASTROCYTOMA; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME DELETION 19Q; CHROMOSOME DELETION 1P; COHORT ANALYSIS; CONTRAST ENHANCEMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT; BRAIN TUMOR; CANCER GRADING; CHROMOSOME 1; CHROMOSOME 19; DISEASE COURSE; FOLLOW UP; GENETICS; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84891549620     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not142     Document Type: Article

References (33)

1. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9(9):906-920
2. HyginodaCruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978-1985
3. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-461
4. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63(3):535-537
5. Brandes AA, Franceschi E, Tosoni A, et al. MGMTpromoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192-2197
6. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113(2):405-410
7. Kang HC, Kim CY, Han JH, Choe GY, Kim JH, KimIA. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: Potential role of p53. J Neurooncol. 2011;102(1):157-162
8. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-1479
9. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-Term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343
10. van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951. Clin Cancer Res. 2011;17(22):7148-7155
11. Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study. J Clin Oncol. 2006;24(29):4746- 4753
12. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2005;113(3):379-385
13. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27(35):5881-5886
14. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150-4154
15. Li S, Yan C, HuangL, Qiu X, Wang Z, Jiang T. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: A single institutional review of 77 patients from China. Neuro Oncol. 2012; 14(1):109-116
16. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):1963-1972
17. van den Bent MJ, Wefel JS, Schiff D, et al. Response Assessment in Neuro-Oncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011; 12(6):583-593
18. Hegi ME, Diserens AC, Gorlia T, et al.MGMT gene silencing and benefit from temozolomide in glioblastoma.N Engl JMed. 2005;352(10):997-1003
19. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: A marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006; 60(6):740-743
20. Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: First Indian report with review of challenges for use in customized treatment. Neurosurgery. 2010; 67(6):1681-1691
21. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol. 2002;103(3):267-275
22. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002;161(1):313-319
23. Ren X, Cui X, Lin S, et al. Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One. 2012;7(3):e32764
24. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177(6):2708-2714
25. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004; 108(1):49-56
26. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997; 56(10):1098-1104
27. Huang L, Jiang T, Yuan F, et al. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: A clinicopathological study. Neuropathol Appl Neurobiol. 2009;35(4):367-379
28. Qu M, Olofsson T, Sigurdardottir S, et al. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol. 2007;113(2):129-136
29. Shamsara J, Sharif S, Afsharnezhad S, et al. Association betweenMGMT promoter hypermethylation and p53mutation in glioblastoma. Cancer Invest. 2009;27(8):825-829
30. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003;13(2):176-184
31. Watanabe T, Katayama Y, Yoshino A, et al. Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol. 2007;17(1):5-10
32. Groenendijk FH, Taal W, Dubbink HJ, et al. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol. 2011;101(3):405-417
33. Wang Y, Li S, Chen L, et al. Glioblastoma with an oligodendroglioma component: Distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14(4):518-525